← All trials
NCT02465060
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 12, 2015
- Primary completion
- Jun 30, 2022
- Completion date
- —
- First posted
- —
- Last posted
- —
- Enrollment
- 6452
- Arms / groups
- 30 / —
- Source
- AACT · pre-existing
Sponsors
- National Cancer Institute (NCI)Lead sponsor
- ECOG-ACRIN Cancer Research GroupOverall official - principal investigator
Drugs studied
Indications studied
- Squamous Cell Carcinoma of Head and Neck
- Bile Duct Neoplasms
- Urinary Bladder Neoplasms
- Breast Neoplasms
- Uterine Cervical Neoplasms
- Colonic Neoplasms
- Esophageal Neoplasms
- Glioma
- Kidney Neoplasms
- Liver Neoplasms
- Lung Neoplasms
- Lymphoma
- Melanoma
- Multiple Myeloma
- Neoplasm Metastasis
- Neoplasms
- Ovarian Neoplasms
- Pancreatic Neoplasms
- Prostatic Neoplasms
- Skin Neoplasms
- Stomach Neoplasms
- Thyroid Neoplasms
- Uterine Neoplasms
- Colorectal Neoplasms
- Endometrial Neoplasms
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.